Live Breaking News & Updates on Stellvertretender pressesprecher

Stay informed with the latest breaking news from Stellvertretender pressesprecher on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Stellvertretender pressesprecher and stay connected to the pulse of your community

DEAL Consortium and Wiley Sign New 5-Year Open Access Agreement

DEAL Consortium and Wiley Sign New 5-Year Open Access Agreement
nachrichten.idw-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nachrichten.idw-online.de Daily Mail and Mail on Sunday newspapers.

Berlin , Germany , German , Stellvertretender-pressesprecher , Freie-universit , Ralf-kellershohn , Liz-ferguson , Wiley-research-publishing , Twitter , Alliance-of-german-science-organizations , Linkedin , Alliance-of-science-organizations

Boehringer Ingelheim: New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase

Boehringer Ingelheim: New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention
BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical research
Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF's expertise in virology, immunology and clinical investigation with Boehringer Ingelheim's expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.

Germany , German , Stabsabteilung-unternehmenskommunikation , Boehringer-ingelheim , Stephan-becker , Stabsstelle-hochschulkommunikation , Florian-klein , Gabriele-neumann , Christoph-wanko , Linda-ruckel , Michel-pairet , Stellvertretender-pressesprecher